UCB is a global biopharmaceutical company, with a focus on neurology and immunology.
Our business is strong. Total revenue grew to $4.5 billion in 2017. We are more than 7,500 people in all four corners of the globe, inspired by patients and driven by science.
Looking ahead, we have a solid platform for continuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of a potential medicine to help patients with osteoporosis. At the same time, we are very excited about the progress in our early research pipeline